Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

SML0042

Sigma-Aldrich

Lazabemide hydrate

≥97% (HPLC)

Synonym(e):

N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

10 MG
CHF 70.10
50 MG
CHF 339.00

CHF 70.10

Check Cart for Availability
Alle Fotos(1)

Größe auswählen

Ansicht ändern
10 MG
CHF 70.10
50 MG
CHF 339.00

About This Item

Empirische Formel (Hill-System):
C8H10ClN3O · xH2O
CAS-Nummer:
103878-84-8
Molekulargewicht:
199.64 (anhydrous basis)
MDL-Nummer:
MFCD20488051
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329825112
NACRES:
NA.77

CHF 70.10

Check Cart for Availability

Assay

≥97% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

white to tan

Löslichkeit

DMSO: ≥22 mg/mL

Ersteller

Roche

Lagertemp.

room temp

SMILES String

O.NCCNC(=O)c1ccc(Cl)cn1

InChI

1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2

InChIKey

JYWYNPKXSLPWGV-UHFFFAOYSA-N

Anwendung

Lazabemide hydrate may be used in cell signaling studies.

Biochem./physiol. Wirkung

Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease[1] and in combination with nicotine replacement therapy aids in smoking cessation.[2]
Selective MAO-B inhibitor; Antiparkinson

Leistungsmerkmale und Vorteile

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H302,H319

Gefahreneinstufungen

Acute Tox. 4 Oral - Eye Irrit. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
071M4718V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

R Raddatz et al.
The Journal of pharmacology and experimental therapeutics, 292(3), 1135-1145 (2000-02-25)
A series of phenoxy-substituted methylimidazoline derivatives were synthesized and used to define the ligand recognition properties of the imidazoline-binding domain (IBD) on monoamine oxidase (MAO)-B and its role in substrate processing. The rank order of potency for selected compounds in
Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
A M Cesura et al.
Advances in neurology, 80, 521-528 (1999-07-20)
V Petegnief et al.
Neuroscience, 94(1), 105-115 (1999-12-29)
Previous data from our laboratory indicate that 25 mM ibotenic acid induces intracellular calcifications in the rat basal forebrain. Because of the lack of specificity of ibotenic acid for a glutamate receptor subtype, a dose-response study with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate was
Ivan Berlin et al.
Addiction (Abingdon, England), 97(10), 1347-1354 (2002-10-03)
Previous research has shown that smokers have reduced brain and platelet monoamine oxidase B (MAOB) activity. This is probably due to some components of tobacco smoke. When smokers quit, MAOB activity returns to normal. Reduced MAO activity may increase nicotine's
R P Mason et al.
Biochemical pharmacology, 60(5), 709-716 (2000-08-06)
Free radical-induced damage to lipid and protein constituents of neuronal membranes contributes to the pathophysiology of neurodegenerative diseases, including Alzheimer's disease (AD). The development of an effective inhibitor of oxidative stress represents an important goal for the treatment of AD.
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.